Online inquiry

IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11893MR)

This product GTTS-WQ11893MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR2 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123041.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 729230
UniProt ID P41597
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11893MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8662MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ5518MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ10662MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ8094MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ7735MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ9918MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ6771MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ10718MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW